בת 46, BMI=31.9 (עלייה של 8 ק”ג בשנתיים האחרונות), וגורמי סיכון קרדיומטבוליים ברקע.

מהן מטרות הטיפול
בנוסף לירידה במשקל?

וויגובי® הוא הטיפול היחיד שהוכיח גם ירידה משמעותית במשקל וגם הפחתה בסיכון לתמותה או לתחלואה קרדיוווסקולרית ^#,2,4

# in patients with BMI ≥ 27 and ASCVD without T2D

References:

1. Alissou M, Demangent T, Folope V, et al. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Diabetes Obes Metab. 2025;1-10
2. Lincoff AM, et al. N Engl J Med. 2023;389(24):2221-2232.; SELECT
3. Divino V, et al. Oral-060. Presented at: ObesityWeek; Nov. 4-7, 2025; Atlanta SCORE primary
4. Wegovy® IL SPC as approved by MOH.
5. Wilding, John PH, et al. New England Journal of Medicine 384.11 (2021): 989-1002. STEP 1
6. Davies, Melanie, et al. The Lancet 397.10278 (2021): 971-984. STEP 2
7. Arnaut T, Hartaigh BO, Byrne K, et al. Impact on food noise after initiating semaglutide treatment: results from a US survey (INFORM). Oral presentation at the European Association for the Study of Diabetes Annual Meeting 2025; 15 – 19September 2025; Vienna, Austria

Semaglutide 2.4mg (Wegovy®) is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance.

For complete information please refer to the updated physician leaflet in the MOH website.
For information on the approved product’s indications, most common adverse events, and significant warnings, enter the following link: Wegovy_aPI

Need additional information? Contact the Marketing Authorization Holder at: www.novonordisk.co.il